Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Bayer expects 2025 to be the most difficult year of its turnaround
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Mistry is a seasoned finance professional having an extensive work experience spanning more than 25 years
The company does not expect this development to have any material impact on the current business operations
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement
Subscribe To Our Newsletter & Stay Updated